For help on how to get the results you want, see our search tips.
222 results
Medicine
Shortages Remove Shortages filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Medicine type
Biosimilar Remove Biosimilar filter
Conditional approval Remove Conditional approval filter
Orphan medicine Remove Orphan medicine filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Polivy
polatuzumab vedotin, Lymphoma, B-Cell
Date of authorisation: 16/01/2020,
, 
, 
, Revision: 2, Authorised, Last updated: 15/12/2020
-
List item
Human medicine European public assessment report (EPAR): Blenrep
belantamab mafodotin, Multiple Myeloma
Date of authorisation: 25/08/2020,, , , Authorised, Last updated: 15/12/2020
-
List item
Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria)
insulin glargine, Diabetes Mellitus
Date of authorisation: 09/09/2014,
, Revision: 10, Authorised, Last updated: 14/12/2020
-
List item
Human medicine European public assessment report (EPAR): Myalepta
Metreleptin, Lipodystrophy, Familial Partial
Date of authorisation: 29/07/2018,, , 
, Revision: 5, Authorised, Last updated: 10/12/2020
-
List item
Human medicine European public assessment report (EPAR): Kanuma
sebelipase alfa, Lipid Metabolism, Inborn Errors
Date of authorisation: 28/08/2015,, 
, , Revision: 6, Authorised, Last updated: 10/12/2020
-
List item
Human medicine European public assessment report (EPAR): Kaftrio
ivacaftor, tezacaftor, elexacaftor, Cystic Fibrosis
Date of authorisation: 21/08/2020,, , Revision: 1, Authorised, Last updated: 09/12/2020
-
List item
Human medicine European public assessment report (EPAR): Aybintio
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020,, , Revision: 1, Authorised, Last updated: 09/12/2020
-
List item
Human medicine European public assessment report (EPAR): Caprelsa
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, , Revision: 18, Authorised, Last updated: 07/12/2020
-
List item
Human medicine European public assessment report (EPAR): Libtayo
Cemiplimab, Carcinoma, Squamous Cell
Date of authorisation: 28/06/2019,, , Revision: 5, Authorised, Last updated: 07/12/2020
-
List item
Human medicine European public assessment report (EPAR): Onpattro
patisiran sodium, Amyloidosis, Familial
Date of authorisation: 27/08/2018,, , , Revision: 8, Authorised, Last updated: 04/12/2020
-
List item
Human medicine European public assessment report (EPAR): Esbriet
Pirfenidone, Idiopathic Pulmonary Fibrosis
Date of authorisation: 27/02/2011,, Revision: 26, Authorised, Last updated: 03/12/2020
-
List item
Human medicine European public assessment report (EPAR): Remsima
infliximab, Arthritis, Psoriatic, Spondylitis, Ankylosing, Colitis, Ulcerative, Psoriasis, Crohn Disease, Arthritis, Rheumatoid
Date of authorisation: 10/09/2013,, Revision: 21, Authorised, Last updated: 01/12/2020
-
List item
Human medicine European public assessment report (EPAR): Amsparity
adalimumab, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Colitis, Ulcerative, Crohn Disease, Hidradenitis Suppurativa
Date of authorisation: 13/02/2020,, , Revision: 1, Authorised, Last updated: 01/12/2020
-
List item
Human medicine European public assessment report (EPAR): Benepali
etanercept, Arthritis, Psoriatic, Arthritis, Rheumatoid, Psoriasis
Date of authorisation: 13/01/2016,, Revision: 12, Authorised, Last updated: 30/11/2020
-
List item
Human medicine European public assessment report (EPAR): Scenesse
afamelanotide, Protoporphyria, Erythropoietic
Date of authorisation: 22/12/2014,, , , Revision: 7, Authorised, Last updated: 30/11/2020
-
List item
Human medicine European public assessment report (EPAR): Retacrit
epoetin zeta, Anemia, Blood Transfusion, Autologous, Kidney Failure, Chronic, Cancer
Date of authorisation: 18/12/2007,, Revision: 27, Authorised, Last updated: 26/11/2020
-
List item
Human medicine European public assessment report (EPAR): Nepexto
etanercept, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Arthritis, Psoriatic, Spondylarthropathies, Spondylitis, Ankylosing, Psoriasis
Date of authorisation: 20/05/2020,, , Revision: 2, Authorised, Last updated: 26/11/2020
-
List item
Human medicine European public assessment report (EPAR): Aplidin
, Last updated: 26/11/2020
-
List item
Human medicine European public assessment report (EPAR): Zercepac
trastuzumab, Breast Neoplasms, Stomach Neoplasms
Date of authorisation: 27/07/2020,, , Revision: 1, Authorised, Last updated: 26/11/2020
-
List item
Human medicine European public assessment report (EPAR): Silapo
epoetin zeta, Anemia, Blood Transfusion, Autologous, Cancer, Kidney Failure, Chronic
Date of authorisation: 18/12/2007,, Revision: 17, Authorised, Last updated: 25/11/2020
-
List item
Human medicine European public assessment report (EPAR): Lamzede
velmanase alfa, alpha-Mannosidosis
Date of authorisation: 23/03/2018,, , , Revision: 3, Authorised, Last updated: 24/11/2020
-
List item
Human medicine European public assessment report (EPAR): Vyndaqel
tafamidis, Amyloidosis
Date of authorisation: 16/11/2011,, , , Revision: 17, Authorised, Last updated: 23/11/2020
-
List item
Human medicine European public assessment report (EPAR): Imraldi
adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Arthritis, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 24/08/2017,, , Revision: 13, Authorised, Last updated: 20/11/2020
-
List item
Human medicine European public assessment report (EPAR): Darzalex
Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016,, , , Revision: 14, Authorised, Last updated: 20/11/2020
-
List item
Human medicine European public assessment report (EPAR): Ondexxya
andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019,, , Revision: 6, Authorised, Last updated: 20/11/2020